Lexicon Pharmaceuticals (LXRX) announced that Tom Garner is joining the company as senior vice president and chief commercial officer, effective October 9, 2023. In his most recent role, Mr. Garner was the senior vice president and head of the U.S. Cardiovascular and Established Brands business unit at Bristol Myers (BMY).
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LXRX:
- INPEFA® (Sotagliflozin) Receives Preferred Formulary Status With Express Scripts For Medicare Patients
- Tom Garner Joins Lexicon as Senior Vice President and Chief Commercial Officer
- Lexicon to Present Post Hoc Analysis of Scored Clinical Trial at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023
- Lexicon Pharmaceuticals to Participate in the H.C. Wainwright & Co. 25th Annual Global Investment Conference
- Lexicon Announces Series of Presentations Relating to LX9211, Its Investigational Drug for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)